Physician profile
Sayed E Wahezi
NPI 1073750741
$160,553.54
in general payments reported to CMS, 2019-2025
24 companies · $52K in 2025
The $52K reported for 2025 was more than what 99% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,174 · 2020: $24K · 2021: $27K · 2022: $8,896 · 2023: $7,522 · 2024: $36K · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62K · Consulting Fee: $18K · Travel and Lodging: $11K · Food and Beverage: $5,982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $61,512.50 |
| Consulting Fee | $17,685.00 |
| Travel and Lodging | $10,946.46 |
| Food and Beverage | $5,982.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $130,290.98 | 2019-2025 | Wavewriter Alpha Prime 16, General - Therapies, Vercise |
| Trice Medical, INC. | $11,329.95 | 2023-2025 | |
| Vertex Pharmaceuticals Incorporated | $7,823.05 | 2025 | |
| Vertos Medical, INC. | $2,504.05 | 2019-2022 | |
| Medtronic, INC. | $2,176.82 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Synchromedii |
| Abbott Laboratories | $2,062.20 | 2019-2024 | Eterna, Octrode |
| Saluda Medical Americas, INC. | $1,873.47 | 2023-2025 | Evoke, Evoke Scs |
| Relievant Medsystems, INC. | $791.05 | 2023 | Intracept |
| Nevro Corp. | $268.11 | 2021-2022 | |
| Nalu Medical, INC. | $267.01 | 2021 | |
| Abbvie INC. | $191.00 | 2023-2025 | Botox, Ubrelvy |
| Stimwave Technologies Incorporated | $182.52 | 2021-2022 | |
| Mml US, INC. | $149.85 | 2023-2025 | Reactiv8 |
| Globus Medical, INC. | $139.06 | 2019-2025 | Senza |
| Vertiflex, INC. | $118.33 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $90.31 | 2024 | Qutenza |
| Grt US Holding, INC. | $81.23 | 2022 | |
| Spr Therapeutics, INC | $74.59 | 2023-2025 | Sprint Pns System |
| Avanos Medical | $59.32 | 2020-2021 | |
| Si-Bone, INC. | $38.75 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $27.49 | 2021-2022 | |
| Medtronic USA, INC. | $14.40 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sayed Wahezi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.